RxLogic and Epidaurus take AI prior authorisation live on PBM rail
RxLogic and Epidaurus Health have brought automated prior authorisation into live production on a shared pharmacy benefit manager client, connecting Epidaurus's AI-driven clinical review engine directly to RxLogic's cloud-native adjudication platform. The integration means a PBM can run automated PA decisions without migrating away from the system where its claims are already processed.
The technical arrangement gives Epidaurus access to RxLogic's member eligibility data, claim history and PA interfaces, allowing the platform to evaluate incoming authorisation requests against each PBM's own clinical guidelines and to route provider outreach automatically where data gaps need closing. Epidaurus says its platform adapts to existing clinical policy rather than imposing a standardised template, meaning plans retain control over their formulary rules.
The deal
Daina Andries, co-founder and chief executive of Epidaurus Health, said the partnership expands access to "trusted clinical AI informed by current evidence and client-specific benefit criteria, enabling faster, evidence-based prior authorisations." RxLogic chief executive Lori Daugherty described prior authorisation as "one of the most burdensome parts of the pharmacy benefit" and argued that mid-market PBMs have historically been underserved by enterprise tooling built for the largest players.
RxLogic positions itself as a neutral adjudication layer: it does not own a pharmacy or a rebate aggregator, which the company says allows it to serve as a non-conflicted integration rail for specialist technology vendors such as Epidaurus. The modular architecture is described as designed to support future additions in clinical decision support, formulary management and medication access, though no further integration partners or timelines were named in the release.
Market and regulatory context
The announcement arrives against a tightening regulatory backdrop. The CMS Interoperability and Prior Authorization Final Rule, which phases in electronic PA requirements for Medicare Advantage, Medicaid and exchange plans, is pushing the wider industry toward standardised, machine-readable PA workflows. Payers and PBMs that cannot demonstrate electronic processing capability face increasing compliance exposure, making automation tooling a near-term operational necessity rather than a discretionary upgrade.
The broader pharmacy benefits market is also moving away from vertically integrated stacks. A growing number of plan sponsors are assembling benefit programmes from best-of-breed, interoperable components, a trend that creates a structural opening for neutral-rail platforms such as RxLogic and specialist AI vendors such as Epidaurus. Competing PBM technology platforms, including several venture-backed new entrants, are pursuing similar unbundled architectures, and the category is attracting investment as incumbent PBMs face political and regulatory scrutiny over rebate transparency and formulary practices.
Epidaurus has received National Science Foundation Small Business Innovation Research awards to support its research, suggesting early-stage academic and government validation for its clinical AI approach. The company has not disclosed revenue, customer count beyond the one shared client named in this release, or a funding history beyond the NSF grants.
For RxLogic, the live production status of the integration is a meaningful proof point: it moves the partnership beyond a commercial agreement into a demonstrable deployment, which will be the unit of evidence that prospective PBM clients will scrutinise as they evaluate similar automation investments.